ADMA Biologics (ADMA) Reports In-Line Q2 EPS

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $60.13 million versus the consensus estimate of $55.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
• First Hydrogen signs deal to acquire 60% stake in robotics IP firm